177 related articles for article (PubMed ID: 27797308)
1. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
Ingle JN; Parulekar WR
N Engl J Med; 2016 Oct; 375(16):1591. PubMed ID: 27797308
[No Abstract] [Full Text] [Related]
2. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
Sanz A; Del Valle ML
N Engl J Med; 2016 Oct; 375(16):1590. PubMed ID: 27797309
[No Abstract] [Full Text] [Related]
3. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
Smith IE
Breast; 2004 Dec; 13 Suppl 1():S3-9. PubMed ID: 15585377
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
5. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
Winer E
Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
[No Abstract] [Full Text] [Related]
6. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
7. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
8. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
9. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Cunnick G; Mokbel K
Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
[TBL] [Abstract][Full Text] [Related]
10. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
11. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
12. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
14. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
16. Extending aromatase inhibitor adjuvant therapy to 10 years.
Baker H
Lancet Oncol; 2016 Jul; 17(7):e275. PubMed ID: 27321154
[No Abstract] [Full Text] [Related]
17. Extended adjuvant therapy for breast cancer--how much is enough?
Prowell TM; Stearns V
J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
[No Abstract] [Full Text] [Related]
18. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Aapro M
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
[No Abstract] [Full Text] [Related]
19. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
20. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Chlebowski R; Cuzick J; Amakye D; Bauerfeind I; Buzdar A; Chia S; Cutuli B; Linforth R; Maass N; Noguchi S; Robidoux A; Verma S; Hadji P
Breast; 2009 Aug; 18 Suppl 2():S1-11. PubMed ID: 19712865
[No Abstract] [Full Text] [Related]
[Next] [New Search]